Bringing the lung cancer screening community together: a landmark BIR/HLH Lung Cancer Screening Study Day
The BIR/HLH Lung Cancer Screening Study Day marked a pivotal moment for the lung cancer screening (LCS) community, bringing together 240 delegates from across the UK for a high-impact, in-person forum focused on advancing best practice in LCS delivery.
Hosted by The HLH Imaging Group (HLH) in association with the British Institute of Radiology (BIR), and supported by the Roy Castle Lung Cancer Foundation, the study day offered a rare and valuable opportunity to explore the end-to-end LCS pathway. From programme setup and quality assurance to data-driven innovation and the future of screening. With contributions from the national LCS team, programme managers, regional cancer leads, clinicians, medical physicists, and researchers, the event created a truly multidisciplinary space for shared learning, challenge, and collaboration.
Delegates heard directly from national and regional leaders who shared practical insight and real-world experience on how to design, mobilise, and sustain successful LCS programmes. From lessons learned in early LCS delivery to scaling services nationally while embedding quality and consistency, the day focused on what works, why it works, and how to deliver impact at scale.
At the heart of the event was The HLH Imaging Group, the UK’s market leader in Lung Cancer Screening teleradiology reporting. HLH currently reports over 32,000 LCS studies every month, supporting NHS services at scale while maintaining clinical excellence. This is underpinned by HLH’s secure, seamless, cloud-based PACS infrastructure, designed specifically for high-volume screening environments and fully integrated with multiple AI providers to support efficiency and innovation.
The study day showcased how technology, data, and clinical expertise can come together to deliver safe, scalable, and future-ready LCS services -and why collaboration across the system is essential as screening continues to expand nationally.
With outstanding attendance, expert speakers, and open, practical discussion, the BIR/HLH Lung Cancer Screening Study Day reinforced its reputation as a leading national forum for all things LCS – and a clear signal of the independent sector’s shared commitment to improving early detection and outcomes for patients across the UK.
If you’d like to learn more about how The HLH Imaging Group can support your Lung Cancer Screening Programme, please contact info@thehlhgroup.com.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.
